REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.75
Bid: 34.50
Ask: 35.00
Change: 0.00 (0.00%)
Spread: 0.50 (1.449%)
Open: 34.75
High: 34.75
Low: 34.75
Prev. Close: 34.75
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

27 Sep 2006 09:30

China Real Estate Opportunities SA 27 September 2006 27 September 2006 China Real Estate Opportunities S.A. Interim Results for the period ended 30 June 2006 CHAIRMAN'S STATEMENT I am pleased to announce the maiden interim results of your Company, China RealEstate Opportunities S.A. ("CREO" or "the Company"), for the period from itsincorporation on 6 December 2005 to 30 June 2006. For the period under review the Company made an operating loss of €2.04 millionand had net cash of €19.54 million at the end of the period. Your Board continues to evaluate a number of potential transactions in Chinaand, although we have not to date considered any suitable to progress tocontract stage, I am pleased to report that a number of promising prospectiveacquisitions are now under consideration. We apply strict criteria whenevaluating transactions and undertake comprehensive due diligence. Whilst thisis very time-consuming it is, we believe, critical to the process to ensure thatwe only contract for the right deals after in-depth research. It would be wrongat this stage in the Company's development to give forward indications on timingbut shareholders will be kept informed on developments. CREO, through its associate Treasury Holdings, has committed significantresources to China and has two Directors now working full time in Shanghai,complemented by approximately 15 other full time staff, researching andassessing potential transactions. The Board is encouraged by the continuing strong growth of the Chinese economyand in particular by the outstanding opportunities in the Chinese real estatemarket. China's GDP continued its strong upward trend, increasing by 10.3% in the yearto March 2006 while retail sales in the first 6 months of 2006 were 13.3% higherthan in the first 6 months of 2005, with the larger urban centres of Beijing andShanghai experiencing even higher GDP growth rates. Prime rents and capital values across all sectors continued to increase in mostparts of China during 2006. During the second quarter of the year, Shanghaioffice rents increased by 3.1%, retail rents by 3.8% and luxury residentialrents by 1.3%. These growth rates were driven by lack of supply of quality spaceand robust demand from multinational corporations. The growth in demand fromforeign companies is expected to continue in the future as World TradeOrganisation driven economic reforms are implemented. A recent study by PricewaterhouseCoopers in association with the Urban LandInstitute, a US based research institute, ranked Shanghai first in the AsiaPacific area in terms of investment and development prospects and third in termsof the real estate market's potential. Outlook Your Board remains confident that CREO will build up a substantial portfolio ofdevelopment and investment opportunities in China and looks forward to updatingshareholders in due course. Ray HorneyChairman Enquiries to: CREORay Horney, ChairmanTel: +44 (0)1273 775225Guy Leech, Group Finance DirectorTel: +353 1 6189300 Teather & GreenwoodPaul FinchamTel: +44 (0)20 7426 7736 Bankside ConsultantsSimon RothschildOliver WintersTel: +44 (0)20 7367 8871 --------------------------- ---------Income Statement 2006From 6 December 2005 to 30 June 2006 •--------------------------- --------- Operating Expenses (2,229,307)Investment income 191,521 --------- Loss before taxation (2,037,786) Income tax expense - ---------Loss for the period (2,037,786) ========= ---------Loss per share (in Euro cent) (0.09) ========= --------------------------- ---------Balance Sheet 2006As at 30 June 2006 •--------------------------- --------- Current assets Cash and cash equivalents 19,541,266Debtors: amounts falling due within one year 2,865,102 =========Total assets 22,406,368 ========= Equity Issued capital 23,000,000Share option reserve 750,000Retained loss (2,037,786) ---------Shareholders' funds - equity 21,712,214 --------- Total current liabilities Trade and other payables 694,154 -------- ---------Total equity and liabilities 22,406,368 --------- -------------------------- --------Cash Flow statement 2006Period ended 30 June 2006 •-------------------------- -------- Operating activities Loss for the period (2,037,786)Share based payments 750,000Increase in debtors (2,865,102)Increase in trade and other payables 694,154 --------Net cash outflow from operating activities (3,458,734) ======== Financing activities 2006 • Issuance of share capital 23,000,000 --------Net cash inflow from financing activities 23,000,000 ========Increase in cash and cash equivalents 19,541,266 ======== Notes:Forming part of the financial statements 1. Basic loss per share The calculation of the basic earnings per share is based on the following data: 2006 • ---------Attributable earnings (2,037,786)Weighted average number of shares 23,000,000 ---------Loss per share (in Euro cent) (0.09) ========= 2. Income tax expense In the jurisdiction that the company is registered, the income tax rate is nil,as other forms of taxation are applied. 2006 • --------Current tax:Corporation tax at 0% (2004: 0%) on the loss for the period on ordinary activities - --------Total current tax - ======== 3. Employees and remuneration The Company did not employ any persons during the period, save for the directorswho received no remuneration during the financial period. 4. Debtors: amounts falling due within one year The debtor balance at 30 June 2006 included a refundable deposit of €2,819,852.This amount was repaid in full to the company on 7 July 2006. 5. Equity 2006 • --------Authorised:20,000,000 ordinary shares of €1.25 each 25,000,000 ========= 2006 • ---------Allocated and called up:18,400,000 ordinary shares of €1.25 each 23,000,000 ========= On 6 December 2005 24,800 ordinary shares were issued fully paid as subscribershares at a price of €1.25 each. On 22 December 2005 18,375,200 ordinary shares were issued at a price of €1.25each for cash. 6. Share option reserve Share options have been conditionally granted over 920,000 ordinary shares inthe Company, equivalent to 5 per cent. of its current issued share capital. Theoptions, which were granted on 1 February 2006, are not exercisable before 1February 2008, and their exercise is conditional, inter alia, on the Companyhaving made an acquisition or acquisitions with a gross value of €100 million ormore. The options, exercisable at €1.25 per share being the price at which ordinaryshares were issued when the Company was launched in December 2005, were grantedto the directors of the Company and others involved in the day to day activitiesof the Company in China. The number of options granted to directors of theCompany is as follows: No of share optionsRichard Barrett 365,000Raymond Horney 75,000Guy Leech 75,000Rory Williams 75,000 The share option reserve represents the directors' interim fair value provisionfor the share options conditionally granted. 7. Reconciliation of movements in shareholders' funds and profit and lossaccount 2006 • Total recognised losses for the period (2,037,786) Opening shareholders' funds - equity - Share option reserve 750,000 Share capital issued during the period 23,000,000 ---------Closing shareholders' funds - equity 21,712,214 ========= Loss for the financial period (2,037,786) Profit and loss account at beginning of period - ---------Profit and loss account at end of period (2,037,786) ========= 8. The Interim Results have been prepared in accordance with International Financial Reporting Standards (IFRS) and their interpretations adopted by the International Accounting Standards Board (IASB). The Interim Results also comply with IFRS as endorsed by the European Commission. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th May 20247:00 amRNSCreo Medical receives King’s Award for Enterprise
25th Apr 20247:00 amRNSNotice of Results
24th Apr 20247:00 amRNSNHS Speedboat data demonstrates savings
20th Mar 20244:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSWelsh Labour Leader visits Creo’s facilities
13th Mar 20243:05 pmRNSHolding(s) in Company
11th Mar 20242:00 pmRNSLTIP Awards
6th Mar 20244:35 pmRNSHolding(s) in Company
1st Mar 20247:00 amRNSMicrowave Lung Ablation Update
7th Feb 20249:12 amRNSTrading Update - Replacement
7th Feb 20247:00 amRNSTrading Update
5th Feb 20247:00 amRNSStrategic Collaboration with Khalifa University
31st Jan 20247:00 amRNSSpeedboat® UltraSlim roll-out reaches Asia Pacific
22nd Jan 20247:00 amRNSAward of Shares under Share Incentive Plan
10th Jan 20247:00 amRNSFirst use of Speedboat® UltraSlim in Latin America
15th Dec 20237:00 amRNSFirst use of Speedboat® UltraSlim in the USA
13th Dec 20237:00 amRNSFirst European Speedboat® UltraSlim procedure
7th Nov 20237:00 amRNSCapital Markets Day
1st Nov 20237:00 amRNSSpeedboat® UltraSlim: US FDA Clearance
25th Oct 20237:00 amRNSSB UltraSlim: EU launch accelerated by 18 months
16th Oct 202310:16 amRNSChange of Nominated Adviser and Joint Broker
12th Oct 20237:00 amRNSInvestor Presentation
12th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSNotice of Results
16th Aug 20237:00 amRNSRoyal Oldham SSD service update
3rd Aug 20237:00 amRNSHalf Year Trading Update
28th Jul 20237:00 amRNSTotal Voting Rights
24th Jul 202310:40 amRNSAward of Shares under Share Incentive Plan
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.